Malignant mesothelioma associated antigens recognized by tumor infiltrating B cells. -usefulness of antibody titer to the antigens -
肿瘤浸润 B 细胞识别恶性间皮瘤相关抗原。
基本信息
- 批准号:18591570
- 负责人:
- 金额:$ 2.44万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2006
- 资助国家:日本
- 起止时间:2006 至 2007
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Malignant pleural mesothelioma is difficult to be diagnosed at early stage and universally accepted therapy has not been established. In this study, we tried to obtain tumor specific antibody derived from tumor infiltrated B lymphocytes (TIB) in malignant mesothelioma by using xenotransplanted SCID mice model, and applied TIB-produced IgG to serological identification of antigens by recombinant expression cloning method (SEREX).Surgical specimens from 5 patients with malignant mesothelioma have been tried to establish tumor cell lines, and also these mesothelioma tissues were engrafted subcutaneously in SCID mice and blood samples were obtained every 2 weeks after xenotransplantation. Two mesothelioma cell lines have been established (K921MS0 and L324MSO). cDNA library was constructed from a tumor cell line (K921MS0) of malignant mesothelioma. Immunoscreening of the library was performed using the serum from SCID mice transplanted with mesothelioma tissues. Immuno-reactive cDNA clones … More were subcloned, and analyzed using database for homology search. Antibodies titers against the identified antigens were analyzed in sera of patients with malignant mesothelioma.Immunohistochemical staining revealed that B lymphocytes infiltrated in tumor tissues. In all SCID mouse serum, human IgG antibody could be detected (ranged from 134 to 24000μg/ml). By using antibodies derived from TIB, 11 antigens were identified. Six antigens showed over expression for malignant mesothelioma. Antibodies against the 6 antigens could be detected not only in serum of SCID mouse but also in sera of mesothelioma patients. Among them, antibody against Gene-X was detected in 7 out of 12 mesothelioma patients, and antibody against Thrombospondin-2 was detected in 11 out of 12 mesothelioma patients.Our results suggest that the B cells infiltrated in the tumor tissues have been sensitized and produced antibody against tumor associate antigens. Among the SEREX defined antigens, 2 antigens (Gene-X and Thrombosponddin-2) were overexpressed in malignant mesothelioma, and antibodies against them could be detected in higher proportion of mesothelioma patients than normal healthy persons. These two antigens could be used as tumor markers for diagnosis of patients with malignant mesothelioma. Less
恶性胸膜间皮瘤早期诊断困难,治疗方法尚未确立。本研究利用SCID小鼠移植瘤模型,从恶性间皮瘤中肿瘤浸润的B淋巴细胞(TIB B lymphocyte,TIB)中提取肿瘤特异性抗体,应用重组表达克隆法(SEREX)进行抗原的血清学鉴定。并将这些间皮瘤组织皮下移植到SCID小鼠中,异种移植后每2周采集血样。已经建立了两种间皮瘤细胞系(K921 MS 0和L324 MSO)。从恶性间皮瘤肿瘤细胞系(K921 MS 0)构建了cDNA文库。使用来自移植有间皮瘤组织的SCID小鼠的血清进行文库的免疫筛选。免疫反应性cDNA克隆 ...更多信息 亚克隆,并使用数据库进行同源性搜索。恶性间皮瘤患者血清中抗所鉴定抗原的抗体滴度分析,免疫组化染色显示肿瘤组织中有B淋巴细胞浸润。在所有SCID小鼠血清中均能检测到人IgG抗体(范围为134 ~ 24000μg/ml)。通过使用TIB衍生的抗体,鉴定了11种抗原。恶性间皮瘤中有6种抗原呈过表达。这6种抗原的抗体不仅在SCID小鼠血清中检测到,而且在间皮瘤患者血清中也检测到。其中7例检测到Gene-X抗体,11例检测到Thrombospondin-2抗体,提示肿瘤组织中浸润的B细胞已被致敏并产生抗肿瘤相关抗原的抗体。在SEREX定义的抗原中,2种抗原(Gene-X和Thrombosponddin-2)在恶性间皮瘤中过表达,并且在间皮瘤患者中可以检测到针对它们的抗体的比例高于正常健康人。这两种抗原可作为诊断恶性间皮瘤的肿瘤标志物。少
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cytokine production of lung cancer cell lines:Correlation between their production and the inflamnatory/immunological responses both in vivo and in vitro
肺癌细胞系的细胞因子产生:其产生与体内和体外炎症/免疫反应之间的相关性
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Fukuyama;T.
- 通讯作者:T.
悪性胸膜中皮腫に対する液性免疫応答の解析
恶性胸膜间皮瘤的体液免疫反应分析
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Shigematsu;Y.;花桐 武志;Shigematsu Y;重松 義紀;重松 義紀;重松 義紀;花桐 武志
- 通讯作者:花桐 武志
Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma
- DOI:10.1158/0008-5472.can-05-3840
- 发表时间:2006-05-01
- 期刊:
- 影响因子:11.2
- 作者:Fukuyama, Takashi;Hanagiri, Takeshi;Yasumoto, Kosei
- 通讯作者:Yasumoto, Kosei
悪性胸膜中皮腫における腫瘍抗原ならびに自己抗原に対する液性免疫応答の解析
恶性胸膜间皮瘤对肿瘤抗原和自身抗原的体液免疫反应分析
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Yasuda;M.;Takenoyama M;Fukuyarna T;Mizukami M;Yasuda M;Yasuda M;Mizukami M;Fukuyama T;Takenoyama M;花桐 武志;重松 義紀
- 通讯作者:重松 義紀
石綿関連肺癌症例における腫瘍浸潤B細胞由来の抗体を用いた腫瘍抗原の同定
使用石棉相关肺癌病例中肿瘤浸润 B 细胞衍生的抗体鉴定肿瘤抗原
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Shigematsu;Y.;花桐 武志
- 通讯作者:花桐 武志
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HANAGIRI Takeshi其他文献
HANAGIRI Takeshi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HANAGIRI Takeshi', 18)}}的其他基金
Clinical Significance of Regulatory T Cells in Regional Lymph Node Lymphocytes of Non-Small-Cell Lung Cancer and overcoming immune-escape mechanism
非小细胞肺癌区域淋巴结淋巴细胞调节性T细胞及克服免疫逃逸机制的临床意义
- 批准号:
23592079 - 财政年份:2011
- 资助金额:
$ 2.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of novel treatment strategy based on the biological characteristics of esophageal squamous cell carcinoma.
根据食管鳞癌的生物学特性建立新的治疗策略。
- 批准号:
20591582 - 财政年份:2008
- 资助金额:
$ 2.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)
肿瘤抗原靶向纳米颗粒治疗胶质母细胞瘤 (GBM)
- 批准号:
10706449 - 财政年份:2023
- 资助金额:
$ 2.44万 - 项目类别:
A Novel Vaccine Strategy to Target Breast Cancer Enabled by Proprietary Mutant Bacteriophage Qbeta-Tumor Antigen Conjugates
由专有突变噬菌体 Qbeta 肿瘤抗原缀合物实现的针对乳腺癌的新型疫苗策略
- 批准号:
10081294 - 财政年份:2020
- 资助金额:
$ 2.44万 - 项目类别:
Multiple Tumor Antigen-loaded DC Vaccine for Hepatocellular Cancer
用于肝细胞癌的多种肿瘤抗原负载 DC 疫苗
- 批准号:
8676457 - 财政年份:2010
- 资助金额:
$ 2.44万 - 项目类别:
Multiple Tumor Antigen-loaded DC Vaccine for Hepatocellular Cancer
用于肝细胞癌的多种肿瘤抗原负载 DC 疫苗
- 批准号:
8468580 - 财政年份:2010
- 资助金额:
$ 2.44万 - 项目类别:
Multiple Tumor Antigen-loaded DC Vaccine for Hepatocellular Cancer
用于肝细胞癌的多种肿瘤抗原负载 DC 疫苗
- 批准号:
7780252 - 财政年份:2010
- 资助金额:
$ 2.44万 - 项目类别:
Multiple Tumor Antigen-loaded DC Vaccine for Hepatocellular Cancer
用于肝细胞癌的多种肿瘤抗原负载 DC 疫苗
- 批准号:
8256634 - 财政年份:2010
- 资助金额:
$ 2.44万 - 项目类别:
Multiple Tumor Antigen-loaded DC Vaccine for Hepatocellular Cancer
用于肝细胞癌的多种肿瘤抗原负载 DC 疫苗
- 批准号:
8101302 - 财政年份:2010
- 资助金额:
$ 2.44万 - 项目类别:
Biomarker Detection Using NAPPA Tumor Antigen Arrays
使用 NAPPA 肿瘤抗原阵列检测生物标志物
- 批准号:
8494123 - 财政年份:2005
- 资助金额:
$ 2.44万 - 项目类别:
Biomarker Detection Using NAPPA Tumor Antigen Arrays
使用 NAPPA 肿瘤抗原阵列检测生物标志物
- 批准号:
8706682 - 财政年份:2005
- 资助金额:
$ 2.44万 - 项目类别:
Biomarker Detection Using NAPPA Tumor Antigen Arrays
使用 NAPPA 肿瘤抗原阵列检测生物标志物
- 批准号:
8882672 - 财政年份:2005
- 资助金额:
$ 2.44万 - 项目类别:














{{item.name}}会员




